Drugs / 18F-Fluciclatide
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02193672 | Aug 2014 → Aug 2020 | high grade malignant neoplasm | M.D. Anderson Cancer Center | Withdrawn | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01633255 | Apr 2012 → Apr 2014 | kidney neoplasm | National Cancer Institute (NCI) | Withdrawn | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01961583 | Sep 2013 → Apr 2016 | kidney neoplasm | Asan Medical Center | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 18F-Fluciclatide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01633255 ↗ |
| Known as | 18F-AH111585 | “[18F] Fluciclatide (previously known as 18F-AH111585) is a new radiopharmaceutical developed for PET imaging, which targets Alpha(v)Beta(3) receptors.” NCT01633255 ↗ |
| Modality | Diagnostic / imaging agent | “a new radiopharmaceutical developed for PET imaging” NCT01633255 ↗ |
| Route | Intravenous | “18F-Fluciclatide, 0.14 mCi/kg (not to exceed 10 mCi), IV(in the vein) administration” NCT01961583 ↗ |